| Identification | Back Directory | [Name]
Benzenesulfonamide, N-[4-[(Z)-[3-[(1-methylcyclohexyl)methyl]-2,4-dioxo-5-thiazolidinylidene]methyl]phenyl]-4-nitro-3-(trifluoromethyl)- | [CAS]
1290069-19-0 | [Synonyms]
OSU-53
Benzenesulfonamide, N-[4-[(Z)-[3-[(1-methylcyclohexyl)methyl]-2,4-dioxo-5-thiazolidinylidene]methyl]phenyl]-4-nitro-3-(trifluoromethyl)- | [Molecular Formula]
C25H24F3N3O6S2 | [MOL File]
1290069-19-0.mol | [Molecular Weight]
583.6 |
| Hazard Information | Back Directory | [Uses]
OSU-53 is an orally active AMPK activator (EC50: 0.3 μM) and a direct mTOR inhibitor. OSU-53 induces autophagy and increases conversion of LC3 I to LC3 II. OSU-53 also modulates energy homeostasis by suppressing fatty acid biosynthesis and shifting the metabolism to oxidation by up-regulating the expression of PGC1α and NRF-1. OSU-53 has antitumor activity in various tumor models, such as breast cancer and thyroid cancer[1][2]. | [References]
[1] Plews RL, et al. A novel dual AMPK activator/mTOR inhibitor inhibits thyroid cancer cell growth. J Clin Endocrinol Metab. 2015 May;100(5):E748-56. DOI:10.1210/jc.2014-1777
[2] Lee KH, et al. Targeting energy metabolic and oncogenic signaling pathways in triple-negative breast cancer by a novel adenosine monophosphate-activated protein kinase (AMPK) activator. J Biol Chem. 2011 Nov 11;286(45):39247-58. DOI:10.1074/jbc.M111.264598 |
|
|